RE:AGM revenue takeaway - $705.6mmBeech, Definitely worth asking Mr. Olds for clarification. I recall the same "lowball" feeling when I first saw the $200M U.S. target on recent BNC PPT (and, even way back to the one time Endo actually put a low estimate in a PPT)...I went to Taylor Collison's Feb 11 report to compare. Don't have your answer but here is their forecast.... Urocidin's "patient pool" for "Incidence" was 5,000 patients for 2015 (launch year) and grew marginally to 5,400/yr by 2021. This would equate to the $200M in sales, so saw some consistency (albeit did not quite understand their methodology). However, Taylor Collison's had another and muuuuch bigger patient pool in their forecast. Yes....you guessed it....patient pool for "prevalence". But of course we don't talk about that pool (openly & directly). But, also to your, DamnYankees and NoNukNuk points, as shareholder's we need to know more (and deserve more having gone to hell and far from back if a longstanding shareholder). I hope you take the time to ask for clarification of your math. Now for sure not accessing BB for quite a while (need to do some work that pays the bill$) rg